A phase 1b trial of blood-brain barrier (BBB)-penetrant tyrosine kinase inhibitor (TKI) tesevatinib in combination with trastuzumab for patients with HER2+metastatic breast cancer (MBC)

被引：1
|
作者：
Jhaveri, Komal L.
Hamilton, Erika Paige
Miller, Kathy
Roche, Maria
Berger, Mark S.
Winer, Eric P.
Lin, Nancy U.
机构：
[1] NYU, Inst Canc, New York, NY USA
[2] Sarah Cannon Res Inst, Brentwood, Essex, England
[3] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[4] Kadmon Corp, Wilmington, MA USA
[5] Kadmon Corp, New York, NY USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.608
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
608
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Determination of the maximum tolerated dose (MTD) of the CNS penetrant tyrosine kinase inhibitor (TKI) tesevatinib administered in combination with trastuzumab in HER2+patients with metastatic breast cancer (BC).
    Lin, Nancy U.
    Freedman, Rachel A.
    Miller, Kathy
    Jhaveri, Komal L.
    Eiznhamer, David A.
    Berger, Mark S.
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] Phase I/II trial of ruxolitinib in combination with trastuzumab in HER2+metastatic breast cancer (MBC)
    Kalinsky, Kevin
    Lee, Shing
    Tiersten, Amy
    Makower, Della F.
    Cigler, Tessa
    Franks, Lauren
    Mundi, Prabhjot
    Chi, Dow-Chung
    Blumberg, Lauren
    Sender, Naomi
    Galazyn, Magdalena
    Hosi, Kristina
    Goel, Anupama
    Klein, Paula
    Andreopoulou, Eleni
    Sparano, Joseph
    Crew, Katherine D.
    Califano, Andrea
    Silva, Jose
    Hershman, Dawn L.
    CANCER RESEARCH, 2020, 80 (04)
  • [3] Phase 1b/2 trial of the HER3 inhibitor patritumab (U3-1287) in combination with trastuzumab plus paclitaxel in newly-diagnosed patients with HER2+metastatic breast cancer (MBC)
    Carraro, S.
    Campos, D.
    Copigneaux, C.
    Saintilien, C.
    Beckman, R. A.
    Korbenfeld, E.
    Coppola, M. P.
    Halabe, K.
    Cazap, E.
    CANCER RESEARCH, 2013, 73
  • [4] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and trastuzumab, in HER2+metastatic breast cancer (MBC)
    Hamilton, Erika Paige
    Yardley, Denise A.
    Hortobagyi, Gabriel N.
    Walker, Luke N.
    Borges, Virginia F.
    Moulder, Stacy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] A phase 1b study of ONT-380, an oral HER2-specific inhibitor, combined with capecitabine and/or trastuzumab, in HER2+metastatic breast cancer (MBC)
    Hamilton, Erika
    Yardley, Denise A.
    Hortobagyi, Gabriel
    Walker, Luke
    Borges, Virginia F.
    Moulder, Stacy
    CANCER RESEARCH, 2015, 75
  • [6] Efficacy results of a phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in HER2+metastatic breast cancer (MBC), including patients (pts) with brain metastases (mets)
    Hamilton, E.
    Borges, V.
    Conlin, A.
    Walker, L.
    Moulder, S.
    CANCER RESEARCH, 2017, 77
  • [7] A phase 1b study of ONT 380, an oral HER2-specific inhibitor, combined with ado trastuzumab emtansine (T DM1), in HER2+metastatic breast cancer (MBC)
    Ferrario, C.
    Hamilton, E.
    Aucoin, N.
    Falkson, C. L.
    Khan, Q.
    Krop, I. E.
    Welch, S.
    Bedard, P. L.
    Conlin, A.
    Chaves, J.
    Vo, A.
    Walker, L.
    Borges, V.
    CANCER RESEARCH, 2016, 76
  • [8] Phase 1b study of ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine (C) and trastuzumab (T) in third line plus treatment of HER2+metastatic breast cancer (MBC).
    Hamilton, Erika Paige
    Yardley, Denise A.
    Hortobagyi, Gabriel N.
    Walker, Luke N.
    Borges, Virginia F.
    Moulder, Stacy L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [9] TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC)
    Lin, N. U.
    Mayer, I. A.
    Hobday, T. J.
    Falkson, C. I.
    Dees, E. C.
    Nanda, R.
    Krop, I. E.
    Rimawi, M. F.
    Wolff, A. C.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] TBCRC 003: Phase II trial of trastuzumab (T) and lapatinib (L) in patients (pts) with HER2+metastatic breast cancer (MBC)
    Lin, N. U.
    Mayer, I. A.
    Najita, J. S.
    Hobday, T. J.
    Falkson, C. I.
    Dees, E. C.
    Rimawi, M. F.
    Nanda, R.
    Gelman, R. S.
    Josephs, K.
    Richardson, A.
    Flores, L.
    Van Den Abbeele, A. D.
    Yap, J. T.
    Arteaga, C. L.
    Wolff, A. C.
    Krop, I. E.
    Winer, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345